Biomedical Engineering Reference
In-Depth Information
78. Wilhelm, S.M., et al.: Preclinical overview of sorafenib, a multikinase inhibitor that targets
both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7(10),
3129-3140 (2008)
79. Escudier, B., et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.
356(2), 125-134 (2007)
80. Llovet, J.M., et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4),
378-390 (2008)
81. Kesisis, G., Broxterman, H., Giaccone, G.: Angiogenesis inhibitors. Drug selectivity and
target specificity. Curr. Pharm. Des. 13(27), 2795-2809 (2007)
82. Shaked, Y., Kerbel, R.S.: Antiangiogenic strategies on defense: on the possibility of blocking
rebounds by the tumor vasculature after chemotherapy. Cancer Res. 67(15), 7055-7058 (2007)
83. Ebos, J.M.L., et al.: Accelerated metastasis after short-term treatment with a potent inhibitor
of tumor angiogenesis. Cancer Cell 15(3), 232-239 (2009)
84. Wells, W.A.: Metastasizing in search of oxygen. J. Cell Biol. 161(4), 669 (2003)
85. Miller, K.D., Sweeney, C.J., Sledge, G.W.: The snark is a boojum: the continuing problem of
drug resistance in the antiangiogenic era. Ann. Oncol. 14(1), 20-28 (2003)
86. Slaton, J.W., et al.: Interferon-alpha-mediated down-regulation of angiogenesis-related genes
and therapy of bladder cancer are dependent on optimization of biological dose and schedule.
Clin. Cancer Res. 5(10), 2726-2734 (1999)